Last update May 16, 2019


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

An antiretroviral integrase inhibitor.
Indicated in combination with two other antiretroviral drugs for the treatment of infection by the human immunodeficiency virus (HIV-1) and in the prophylaxis of vertical transmission (pregnancy/breastfeeding) (Puthanakit 2018, Westling 2012) and accidental post-exposure.
Oral administration in 2 daily doses.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data (moderately high molecular weight and percentage of protein binding, pKa acid and low lipid solubility) hinders transfer to breastmilk in significant quantities.

It is a well-tolerated drug with low frequency of serious side effects (MSD 2019, AEMPS2018, Clarke 2018, Ribera 2010), including in neonates, infants and children (Clarke 2018, Ripamonti 2016, Nachman 2015 and 2014).

It is used in nonpreterm newborns and from 3 kg of weight (Trahan 2019, MSD 2019, AEMPS 2018).
The WHO provides for neonatal use (Clarke 2018, WHO 2016, WHO 2014).
It is recommended after 2 to 4 weeks of life in the non-occupational post-exposure prophylaxis guidelines for HIV (CDC 2016, WHO 2014).

In preterm infants it has a longer elimination half-life, between 15 and 22 hours (Kreutzwiser 2017)

Since the last update, no problems have been reported in newborns and infants whose mothers were taking raltegravir.

See below the information of these related products:


We do not have alternatives for Raltegravir since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Raltegravir is also known as

Raltegravir in other languages or writings:


Raltegravir belongs to this group or family:


Main tradenames from several countries containing Raltegravir in its composition:


Variable Value Unit
Molecular weight 483 daltons
Protein Binding 83 %
pKa 5,62 -
Tmax 1,7 - 3 hours
T1/2 9 (7 - 12) hours


  1. Trahan MJ, Lamarre V, Metras ME, Kakkar F. Use of Triple Combination Antiretroviral Therapy With Raltegravir as Empiric HIV Therapy in the High-risk HIV-exposed Newborn. Pediatr Infect Dis J. 2019 Apr;38(4):410-412. Abstract
  2. MSD. Raltegravir (Isentress). Drug Summary. 2019 Full text (in our servers)
  3. AEMPS - MSD. Raltegravir (Isentress). Ficha técnica. 2018 Full text (in our servers)
  4. Clarke DF, Penazzato M, Capparelli E, Cressey TR, Siberry G, Sugandhi N, Mirochnick M; WHO Paediatric Antiretroviral Working Group.. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol. 2018 Jan;11(1):83-93. Abstract
  5. Puthanakit T, Thepnarong N, Chaithongwongwatthana S, Anugulruengkitt S, Anunsittichai O, Theerawit T, Ubolyam S, Pancharoen C, Phanuphak P. Intensification of antiretroviral treatment with raltegravir for pregnant women living with HIV at high risk of vertical transmission. J Virus Erad. 2018 Apr 1;4(2):61-65. Abstract Full text (link to original source) Full text (in our servers)
  6. Kreutzwiser D, Sheehan N, Dayneka N, Lemire B, Wong A, Samson L, Brophy J. Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV. Antivir Ther. 2017;22(6):545-549. Abstract
  7. CDC - Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States. nPEP Guidelines Update. 2016 Full text (link to original source) Full text (in our servers)
  8. WHO - World Health Organization Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Guideline. 2016 Abstract Full text (link to original source) Full text (in our servers)
  9. Ripamonti D, Tatarelli P, Mangili G, Gotta C, Benatti SV, Bruzzone B, Callegaro A, Viscoli C, Ruggeri M, Di Biagio A. Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates. J Chemother. 2016 Aug;28(4):337-40. Abstract
  10. Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age. J Pediatric Infect Dis Soc. 2015 Dec;4(4):e76-83. Abstract Full text (link to original source) Full text (in our servers)
  11. WHO. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. Guideline. 2014 Full text (link to original source) Full text (in our servers)
  12. Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team.. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis. 2014 Feb;58(3):413-22. Abstract
  13. Westling K, Pettersson K, Kaldma A, Navér L. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS. 2012 Dec;26(12):714-7. Abstract
  14. Ribera E, Tuset M, Martín M, del Cacho E. Características de los fármacos antirretrovirales. [Characteristics of antiretroviral drugs]. Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM